RankAlpha logo
Back to Rankings

IOVA

Iovance BiotherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The stock is depressed versus a median analyst target near $9.56 while Iovance now has a commercial product, a visible launch-conversion setup, and multiple registrational shots on goal beyond current melanoma use.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.6.
What can break
Amtagvi demand may not convert cleanly from center onboarding and Proleukin ordering into sustained infusion volume.
Momentum
83
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.40 · Bull $6.00 · Bear $2.20
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $9.56
Why
Momentum83 · Δ7d -2.6
Value41 · Δ7d +0.1
Sentiment55 · Δ7d +7.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
83
34% active weight
Current posture
7d trendImproving
Δ7d
-2.6
Δ21d
+29.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
55
33% active weight
Current posture
7d trendImproving
Δ7d
+7.6
Δ21d
+0.8
Why this grade

Composite grade B. Momentum 83.0 / Value 41.1 / Sentiment 54.5

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.83B
Beta
0.77
Shares Out
385.46M
P/E (TTM) · Derived
-4.3
P/S (TTM)
3.88
P/FCF (TTM) · Derived
-4.48
Rev YoY
+15.2%
EPS YoY
+9.0%
Gross Margin
+24.0%
Op Margin
-166.3%
Net Debt
-$322.78M
Current Ratio
3.41
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology